Finnegan client Abbott Laboratories filed an infringement suit July 21 in the District of Delaware against Hospira Inc. related to their recent ANDA application seeking approval for three formulations of an injectable version of Abbott’s kidney disease treatment Zemplar®. Over the last year, Abbott has brought suit in the same court against Ben Venue Laboratories for an injectable version of the patented treatment, as well as Roxanne Laboratories and Sandoz Inc. over their generic versions of Zemplar® capsules. Finnegan represents Abbott in all of these matters.
Press Release
Finnegan Earns Spot on National Law Journal’s 2020 Appellate Hot List
November 1, 2020
Press Release
Finnegan Shreds Copyright Case for Dean Guitars and Estate of Pantera Guitarist
December 3, 2018
Media Mention
District Court Cannot Force Discovery in Patent Reexamination But AIA Different
March 29, 2013
Award/Ranking
September 18, 2012
Media Mention
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.